Country: Canada
Language: English
Source: Health Canada
EVEROLIMUS
SANDOZ CANADA INCORPORATED
L04AH02
EVEROLIMUS
2.5MG
TABLET
EVEROLIMUS 2.5MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0152682003; AHFS:
APPROVED
2019-10-04
_Sandoz Everolimus Product Monograph _ _Page _1_ of 95_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR SANDOZ EVEROLIMUS Everolimus Tablets, 2.5 mg, 5 mg, and 10 mg, Oral Protein kinase inhibitors ATC Code: L01XE10 Sandoz Canada Inc. 110 Rue de Lauzon Boucherville, Quebec J4B 1E6 Date of Initial Authorization: January 27, 2020 Date of revision: July 04, 2022 Submission Control Number: 261603 _Sandoz Everolimus Product Monograph _ _Page _2_ of 95_ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Radiation Sensitization and Radiation Recall 07/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ..................................................................................... 2 TABLE OF CONTENTS .......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION............................................................... 4 1 INDICATIONS.............................................................................................................. 4 1.1 Pediatrics ........................................................................................................... 5 1.2 Geriatrics............................................................................................................ 5 2 CONTRAINDICATIONS ............................................................................................... 6 3 SERIOUS WARNINGS AND PRECAUTIONS BOX...................................................... 6 4 DOSAGE AND ADMINISTRATION .............................................................................. 7 4.1 Dosing Considerations ........................................................................................ 7 4.2 Recommended Dose and Dosage Adjustment .................................................... 8 4.3 Reconstitution..................................................................................... Read the complete document